Oak review
Flat at every dose with no subscription, beside an advertised figure whose terms are never published.
The verdict
Oak publishes $250 a month for compounded semaglutide and $300 for tirzepatide. Both are flat at every dose and no subscription is required.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Dose pricing
- Rises with dose
- From
- From $250/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
Oak sells both molecules by injection at one price per dose level. No subscription is required. A code lowers the tirzepatide figure.
Who writes the prescription, and what do they see?
A prescription precedes shipping. The pages state rates and terms. The intake is not documented anywhere a reader can reach.
Two terms are unusually clean: one price at every dose, and no subscription. Against them sits an advertised figure the site never explains, which a reader meets before either.
What happens when the dose goes up?
Both lines are flat at every dose, which answers the price question directly. Nothing describes what clinical support accompanies an increase, and the advertised entry figure has no dose attached at all.
What the price includes
Six months at $250 is $1,500 and tirzepatide at $300 is $1,800. A code brings tirzepatide to $199 against a struck $300. Oak also advertises from $119, and the terms behind that figure are quiz-gated and never published, so it cannot be planned against.
What it claims, and what it cites
Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named.
Where it holds up, and where it does not
- Strength: One price at every dose, both molecules
- Strength: No subscription required
- Strength: A code is published with its figure
- Limitation: Tirzepatide costs $50 more a month
- Limitation: The advertised from figure is quiz-gated
- Limitation: Its terms are never published
- Limitation: No state coverage list is recorded
What the evidence says about this kind of treatment
The assessment above is about Oak. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who wants a flat rate without a subscription and ignores the entry figure.
- Wrong for
- A reader planning from the advertised $119.
The evidence behind what Oak prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Oak compares
| Seller | Who it suits | Go |
|---|---|---|
 Open Water Rx | Readers who want one all-inclusive figure with no code attached | See Open Water Rx → |
 Obu Health | Readers who value a site that agrees with itself | See Obu Health → |
 Options Medical Weight Loss | Readers certain of a year who can pay the whole of it at once | See Options Medical Weight Loss → |
More GLP-1 telehealth sellers reviews: TeleHealth MedTeleHealth Weight SolutionsTelePeptideTeleSlim ClinicTeleZen MDTell Her Doc
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Can I get $119 a month?
- The terms behind that figure are quiz-gated and never published, so nothing on the site establishes how.
- Is a subscription required?
- No. Oak states no subscription is required on either line.
- Does the price rise with the dose?
- No. Both lines are stated flat at every dose.
- Is Oak expensive compared with other GLP-1 telehealth sellers?
- Oak publishes a starting figure of $250/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Oak above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.